Matthew Plunkett
About Matthew Plunkett
Matthew Plunkett - Chief Financial Officer
Matthew Plunkett is a seasoned Chief Financial Officer with a robust background in the biopharmaceutical sector. Over his extensive 25-year career, he has held pivotal financial leadership roles at several prominent companies in the field. His expertise includes spearheading financial strategies and leading major financial transactions, including multiple successful IPOs.
Matthew Plunkett Education and Expertise
Matthew Plunkett holds a Ph.D. in organic chemistry from the University of California, Berkeley, and a B.S. in chemistry from Harvey Mudd College. His academic foundation in chemistry has provided a solid scientific grounding, complementing his extensive experience in financial management within the biopharmaceutical industry.
Matthew Plunkett Background in Biopharmaceutical Sector
With over 25 years of experience, Matthew Plunkett has contributed significantly to the biopharmaceutical sector. His roles have spanned from financial management to strategic business development. Notably, he has served as Chief Financial Officer at Aeovian Pharmaceuticals, Imago Biosciences, and Nkarta Therapeutics. At Imago Biosciences, he led a $155 million Nasdaq IPO, and at Nkarta Therapeutics, he was instrumental in the $290 million Nasdaq IPO.
Matthew Plunkett Career in Financial Leadership
Matthew Plunkett has a long history of financial leadership, starting with various positions at CIBC World Markets and its U.S. successor Oppenheimer & Co., including Managing Director, Head of West Coast Biotechnology. His career in financial leadership is marked by his achievements at CTI BioPharma, where he served as Chief Business Officer, leading multiple financing and corporate development transactions.